Cargando…

Medication adherence and persistence in patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis: a systematic literature review

PURPOSE: Proper adherence and persistence to medications are crucial for better quality of life and improved outcomes in rheumatoid arthritis (RA), psoriasis (PsO), and psoriatic arthritis (PsA). We systematically describe current adherence and persistence patterns for RA, PsO, and PsA, with a focus...

Descripción completa

Detalles Bibliográficos
Autores principales: Murage, Mwangi J, Tongbram, Vanita, Feldman, Steven R, Malatestinic, William N, Larmore, Cynthia J, Muram, Talia M, Burge, Russel T, Bay, Charles, Johnson, Nicole, Clifford, Sarah, Araujo, Andre B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6110273/
https://www.ncbi.nlm.nih.gov/pubmed/30174415
http://dx.doi.org/10.2147/PPA.S167508
_version_ 1783350449852645376
author Murage, Mwangi J
Tongbram, Vanita
Feldman, Steven R
Malatestinic, William N
Larmore, Cynthia J
Muram, Talia M
Burge, Russel T
Bay, Charles
Johnson, Nicole
Clifford, Sarah
Araujo, Andre B
author_facet Murage, Mwangi J
Tongbram, Vanita
Feldman, Steven R
Malatestinic, William N
Larmore, Cynthia J
Muram, Talia M
Burge, Russel T
Bay, Charles
Johnson, Nicole
Clifford, Sarah
Araujo, Andre B
author_sort Murage, Mwangi J
collection PubMed
description PURPOSE: Proper adherence and persistence to medications are crucial for better quality of life and improved outcomes in rheumatoid arthritis (RA), psoriasis (PsO), and psoriatic arthritis (PsA). We systematically describe current adherence and persistence patterns for RA, PsO, and PsA, with a focus on biologics and identifying factors associated with adherence and persistence. PATIENTS AND METHODS: Using various databases, a systematic literature review of US-based studies published from 2000 to 2015 on medication adherence and persistence to biologics and associated factors was conducted among patients with RA, PsO, and PsA. RESULTS: Using the medication possession ratio or the percentage of days covered >80%, RA and PsO adherence rates for etanercept, adalimumab, and infliximab ranged from 16% to 73%, 21% to 70%, and 38% to 81%, respectively. Using the criteria of a ≥45-day gap, RA persistence rates for etanercept, adalimumab, and infliximab ranged from 46% to 89%, 42% to 94%, and 41% to 76%, respectively. In PsO, persistence rates for etanercept and adalimumab ranged from 34% to 50% and 50% to 62%, respectively. Similar persistence rates were observed in PsA. Experienced biologics users showed better adherence and persistence. Younger age, female gender, higher out-of-pocket costs, greater disease severity, and more comorbidities were associated with lower adherence and persistence rates. Qualitative surveys revealed that nonpersistence was partly due to perceived ineffectiveness and safety/tolerability concerns. CONCLUSION: Biologic adherence and persistence rates in RA, PsO, and PsA in the United States were low, with significant opportunity for improvement. Various factors – including decrease in disease severity; reduction of comorbidities; lower out-of-pocket costs; refilling at specialty pharmacies; and awareness of drug effectiveness, safety, and tolerability – can inform targeted approaches to improve these rates.
format Online
Article
Text
id pubmed-6110273
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-61102732018-08-31 Medication adherence and persistence in patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis: a systematic literature review Murage, Mwangi J Tongbram, Vanita Feldman, Steven R Malatestinic, William N Larmore, Cynthia J Muram, Talia M Burge, Russel T Bay, Charles Johnson, Nicole Clifford, Sarah Araujo, Andre B Patient Prefer Adherence Review PURPOSE: Proper adherence and persistence to medications are crucial for better quality of life and improved outcomes in rheumatoid arthritis (RA), psoriasis (PsO), and psoriatic arthritis (PsA). We systematically describe current adherence and persistence patterns for RA, PsO, and PsA, with a focus on biologics and identifying factors associated with adherence and persistence. PATIENTS AND METHODS: Using various databases, a systematic literature review of US-based studies published from 2000 to 2015 on medication adherence and persistence to biologics and associated factors was conducted among patients with RA, PsO, and PsA. RESULTS: Using the medication possession ratio or the percentage of days covered >80%, RA and PsO adherence rates for etanercept, adalimumab, and infliximab ranged from 16% to 73%, 21% to 70%, and 38% to 81%, respectively. Using the criteria of a ≥45-day gap, RA persistence rates for etanercept, adalimumab, and infliximab ranged from 46% to 89%, 42% to 94%, and 41% to 76%, respectively. In PsO, persistence rates for etanercept and adalimumab ranged from 34% to 50% and 50% to 62%, respectively. Similar persistence rates were observed in PsA. Experienced biologics users showed better adherence and persistence. Younger age, female gender, higher out-of-pocket costs, greater disease severity, and more comorbidities were associated with lower adherence and persistence rates. Qualitative surveys revealed that nonpersistence was partly due to perceived ineffectiveness and safety/tolerability concerns. CONCLUSION: Biologic adherence and persistence rates in RA, PsO, and PsA in the United States were low, with significant opportunity for improvement. Various factors – including decrease in disease severity; reduction of comorbidities; lower out-of-pocket costs; refilling at specialty pharmacies; and awareness of drug effectiveness, safety, and tolerability – can inform targeted approaches to improve these rates. Dove Medical Press 2018-08-21 /pmc/articles/PMC6110273/ /pubmed/30174415 http://dx.doi.org/10.2147/PPA.S167508 Text en © 2018 Murage et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Murage, Mwangi J
Tongbram, Vanita
Feldman, Steven R
Malatestinic, William N
Larmore, Cynthia J
Muram, Talia M
Burge, Russel T
Bay, Charles
Johnson, Nicole
Clifford, Sarah
Araujo, Andre B
Medication adherence and persistence in patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis: a systematic literature review
title Medication adherence and persistence in patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis: a systematic literature review
title_full Medication adherence and persistence in patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis: a systematic literature review
title_fullStr Medication adherence and persistence in patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis: a systematic literature review
title_full_unstemmed Medication adherence and persistence in patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis: a systematic literature review
title_short Medication adherence and persistence in patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis: a systematic literature review
title_sort medication adherence and persistence in patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis: a systematic literature review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6110273/
https://www.ncbi.nlm.nih.gov/pubmed/30174415
http://dx.doi.org/10.2147/PPA.S167508
work_keys_str_mv AT muragemwangij medicationadherenceandpersistenceinpatientswithrheumatoidarthritispsoriasisandpsoriaticarthritisasystematicliteraturereview
AT tongbramvanita medicationadherenceandpersistenceinpatientswithrheumatoidarthritispsoriasisandpsoriaticarthritisasystematicliteraturereview
AT feldmanstevenr medicationadherenceandpersistenceinpatientswithrheumatoidarthritispsoriasisandpsoriaticarthritisasystematicliteraturereview
AT malatestinicwilliamn medicationadherenceandpersistenceinpatientswithrheumatoidarthritispsoriasisandpsoriaticarthritisasystematicliteraturereview
AT larmorecynthiaj medicationadherenceandpersistenceinpatientswithrheumatoidarthritispsoriasisandpsoriaticarthritisasystematicliteraturereview
AT muramtaliam medicationadherenceandpersistenceinpatientswithrheumatoidarthritispsoriasisandpsoriaticarthritisasystematicliteraturereview
AT burgerusselt medicationadherenceandpersistenceinpatientswithrheumatoidarthritispsoriasisandpsoriaticarthritisasystematicliteraturereview
AT baycharles medicationadherenceandpersistenceinpatientswithrheumatoidarthritispsoriasisandpsoriaticarthritisasystematicliteraturereview
AT johnsonnicole medicationadherenceandpersistenceinpatientswithrheumatoidarthritispsoriasisandpsoriaticarthritisasystematicliteraturereview
AT cliffordsarah medicationadherenceandpersistenceinpatientswithrheumatoidarthritispsoriasisandpsoriaticarthritisasystematicliteraturereview
AT araujoandreb medicationadherenceandpersistenceinpatientswithrheumatoidarthritispsoriasisandpsoriaticarthritisasystematicliteraturereview